[Usefulness of perospirone for the prevention of nausea related to opioid administration].
OBJECTIVE
In our department, prochlorperazine, a D2 receptor antagonist, was previously administered to prevent nausea related to the introduction of opioids. However, we always had to consider extrapyramidal symptoms. Since August 2006, perospirone has been administered to all patients who have commenced oral opioid therapy, to prevent nausea. In this study, we investigated its usefulness in the prevention of nausea.


METHODS
Perospirone (4 or 8 mg, once a day) was combined in all patients in whom opioid therapy was introduced with oxycodone at 10 mg/day. We retrospectively examined the presence or absence of nausea within 1 week.


RESULTS
Oxycodone-related nausea occurred in 1 of 25 patients. There were no adverse reactions such as extrapyramidal symptoms.


CONCLUSIONS
These results suggest the usefulness of perospirone for the prevention of nausea related to the intro- duction of opioids.
Yomiya
Kinomi
K
Department of Palliative Care, Saitama Cancer Center.
Matsuo
Naoki
N
Okuyama
Shinichirou
S
D000368:Aged; D000369:Aged, 80 and over; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D054833:Isoindoles / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000517:prevention & control*; D012189:Retrospective Studies; D013844:Thiazoles / Q000494:pharmacology*
D000701:Analgesics, Opioid; D054833:Isoindoles; D013844:Thiazoles; C065533:perospirone